Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 9/20 | 0.54 |
| ▸ | CES1 | P23141 | 6/20 | 0.54 |
| ▸ | CES2 | O00748 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Hexanol SCHEMBL7731082 | 1.00 | LMNA (0.59) | LMNAHSD17B10MEN1KMT2AALDH1A1 | |
| Nonanol SCHEMBL271357 | 1.00 | LMNA (0.59) | LMNAHSD17B10MEN1KMT2AALDH1A1 | |
| 1-Heptanol SCHEMBL22557209 | 1.00 | LMNA (0.59) | LMNAHSD17B10MEN1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28259283 | 0.93 | ALDH1A1 (0.52) | LMNAHSD17B10MEN1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5402982 | 0.91 | ALDH1A1 (0.55) | LMNAHSD17B10MEN1KMT2AALDH1A1 | |
| Heptane SCHEMBL1776021 | 0.91 | FAAH (0.58) | HSD17B10MEN1KMT2AALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL28259282 | 0.91 | FAAH (0.54) | HSD17B10MEN1KMT2ASMN1; SMN2FAAH | |
| Heptane SCHEMBL3935940 | 0.91 | FAAH (0.62) | HSD17B10MEN1KMT2AALDH1A1TSHR | |
| Nonane SCHEMBL4255344 | 0.91 | FAAH (0.62) | HSD17B10MEN1KMT2AALDH1A1TSHR | |
| Hexadecane SCHEMBL4765353 | 0.91 | FAAH (0.62) | HSD17B10MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | claimed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | claimed |
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | claimed |
| CN-116500167-A | Method for separating and detecting enantiomer and diastereoisomer of baluo Sha Weizhi | 常州英诺升康生物医药科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-107941970-B | Separation and detection method of D-p-hydroxyphenylglycine and enantiomer thereof | 常州合全药业有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-108624533-B | Method for separating and purifying phenyl lactic acid from lactobacillus plantarum | 浙江工商大学 | 2021-03-09 | — | — | CN | claimed |
| CN-115029329-B | Carbonyl reductase mutant and application thereof in preparation of R-mandelic acid | 上海瀚鸿科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-113945672-B | Method for detecting ticagrelor and related substances thereof | 武汉武药科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113336636-B | Synthesis process of DL-mandelic acid with high yield | 湖州柏特生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| US-20230323317-A1 | NOVEL HYDROLASE AND METHOD FOR PRODUCING (1S,2S)-1-ALKOXYCARBONYL-2-VINYLCYCLOPROPANE CARBOXYLIC ACID USING SAME | API CORPORATION (JP) | 2023-10-12 | — | — | US | disclosed |
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997022591-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997011960-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | JAPAT LTD. (CH) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| US-5457225-A | Process for preparation of 5-hydroxy-3-ketoester derivative and optically active substance thereof | UBE INDUSTRIES LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| US-5434152-A | AIDS, enzyme inhibitor | MERCK & CO., INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995013273-A1 | ASYMMETRIC SYNTHESIS OF (S)-(-)-6-CHLORO-4-CYCLOPROPYL-3,4-DIHYDRO-4-[(2-PYRIDYL)ETHYNYL]-2(1H)-QUINAZOLINONE | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | LMNA 2635/4885HSD17B10 499/4885MEN1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.